ARMO BioSciences Decloaks With $20 Million Cash, Focus On Cancer  
11/25/2013 9:01:58 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ARMO BioSciences Inc. is emerging from stealth mode with powerful science, leaders and funders. The Redwood City company, launched by a trio of former employees at the legendary DNAX Research Institute in Palo Alto, is playing off the boom in cancer immunotherapy research and drugs. But its focus on an extended-play version of the cell-signaling protein interleukin-10, or IL-10, could quickly expand as well into fibrotic diseases, such as the lung-scarring idiopathic pulmonary fibrosis, high cholesterol and inflammatory diseases.

Help employers find you! Check out all the jobs and post your resume.